skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: SL-01, an oral derivative of gemcitabine, inhibited human breast cancer growth through induction of apoptosis

Journal Article · · Biochemical and Biophysical Research Communications
; ;  [1];  [2];  [1]
  1. Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan 250012 (China)
  2. Sanlugen PharmaTech, Rm 506, No. 2766 Yingxiu Road, Jinan 250101 (China)

Highlights: •SL-01 is an oral derivative of gemcitabine. •SL-01 possessed activity against human breast cancer growth via apoptotic induction. •SL-01’s activity was more potently than that of gemcitabine. •SL-01 inhibited cancer growth without toxicity to mice. -- Abstract: SL-01 is an oral derivative of gemcitabine that was synthesized by introducing the moiety of 3-(dodecyloxycarbonyl) pyrazine-2-carbonyl at N4-position on cytidine ring of gemcitabine. We aimed to evaluate the efficacy of SL-01 on human breast cancer growth. SL-01 significantly inhibited MCF-7 proliferation as estimated by colorimetric assay. Flow cytometry assay indicated the apoptotic induction and cell cycle arrest in G1 phase. SL-01 modulated the expressions of p-ATM, p53 and p21 and decrease of cyclin D1 in MCF-7 cells. Further experiments were performed in a MCF-7 xenografts mouse model. SL-01 by oral administration strongly inhibited MCF-7 xenografts growth. This effect of SL-01 might arise from its roles in the induction of apoptosis. Immunohistochemistry assay showed the increase of TUNEL staining cells. Western blotting indicated the modulation of apoptotic proteins in SL-01-treated xenografts. During the course of study, there was no evidence of toxicity to mice. In contrast, the decrease of neutrophil cells in peripheral and increase of AST and ALT levels in serum were observed in the gemcitabine-treated mice. Conclusion: SL-01 possessed similar activity against human breast cancer growth with gemcitabine, whereas, with lower toxicity to gemcitabine. SL-01 is a potent oral agent that may supplant the use of gemcitabine.

OSTI ID:
22242061
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 438, Issue 2; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English

Similar Records

SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine
Journal Article · Wed Aug 01 00:00:00 EDT 2012 · Toxicology and Applied Pharmacology · OSTI ID:22242061

Cordycepin-induced apoptosis and autophagy in breast cancer cells are independent of the estrogen receptor
Journal Article · Thu Dec 15 00:00:00 EST 2011 · Toxicology and Applied Pharmacology · OSTI ID:22242061

Growth suppression of MCF-7 cancer cell-derived xenografts in nude mice by caveolin-1
Journal Article · Fri Nov 07 00:00:00 EST 2008 · Biochemical and Biophysical Research Communications · OSTI ID:22242061